Dear Editor,
Histone H3 lysine 4 (H3K4) methylation is closely correlated to gene transcription activation [1] . In mammals, the MLL family (also called KMT2) histone methyltransferase, which includes MLL1 to 4, SET1A, and SET1B, are the principal enzymes that carry out the global methylation of H3K4 in vivo [1] . In contrast to other SET domain-containing histone methyltransferases, MLL family proteins exhibit very low intrinsic histone methyltransferease (HMT) activity by themselves. Their full activity is only achieved in the presence of WDR5, Ash2L, RbBP5, and DPY30, the common regulatory components of all MLL family complexes [2] . Ash2L (Absent, small or homeotic discs-like 2) is a trithorax group protein, and a critical regulator of all MLL complexes. Knockdown of Ash2L results in a global reduction of histone H3K4 trimethylation [3] . The role of Ash2L in methylation regulation is dependent on its two binding partners, RbBP5 and DPY30 [2, 4] . The interaction between Ash2L and RbBP5 is essential for MLL1 complex integrity and activity regulation [2, 5] . The Ash2L-DPY30 interaction was recently reported to be important for the regulation of nucleosomal H3K4 trimethylation and the differentiation potential of embryonic stem cells [6] . Ash2L protein adopts a modular configuration. From the N-to the Cterminus, it contains a PHD finger, a WH motif, an SPRY domain, and a DPY-30 binding-motif (DBM) ( Figure  1A ). The SPRY domain is the primary moiety in Ash2L that recognizes RbBP5, mediates MLL1 complex assembly, and regulates MLL1 enzymatic activity [5] . Here we report the crystal structure of SPRY domain of Ash2L, and dissect its interactions with RbBP5 and DPY30.
Bioinformatical and biochemical analyses suggested that the SPRY domain of Ash2L contains a large 44-residue unstructured loop (residues 402-445) in the middle of the domain (Supplementary information, Figure S1A , S1B and S1C). An Ash2L construct (Ash2L SPRY ) with a deletion of this loop retains the same HMT activity as the full-length Ash2L (Supplementary information, Figure S1D ). We determined the crystal structure of Ash2L SPRY using the single-wavelength anomalous dispersion method with mercury (MeHgAc)-derivative crystals, and refined to a resolution of 2.1 Å (Supplementary information, Table S1 ). The high-quality experimental electron density map enabled us to fit and refine the structure except for the C-terminal 13 residues (residues 511-523).
Ash2L SPRY adopts a tadpole-like conformation with three recognizable modules, an 11-residue N-terminal pre-SPRY motif, a central 200-residue globular fold that forms the core of Ash2L SPRY , followed by a 25-residue C-terminal post-SPRY motif ( Figure 1B ). Both the pre-SPRY and the post-SPRY motifs are short and composed of a 3 10 helix and either one or two β strands ( Figure  1B ). These two motifs form a two-stranded β sheet that protrudes from the globular SPRY domain, forming the tail of the tadpole-like structure ( Figure 1B) . The post-SPRY motif makes extensive contacts with one side of the β-sandwich of Ash2L SPRY and thus plays an important role in stabilizing the core of the SPRY domain (Supplementary information, Figure S2A ). The central core of Ash2L SPRY adopts a distorted β-sandwich conformation, consisting of two layers of concave-shaped β-sheets ( Figure 1B ). All these β strands are arranged in an antiparallel configuration. The two β-sheet layers stack together mainly through Van der Waals contacts by a group of hydrophobic residues (Supplementary information, Figure S2B ). These internal hydrophobic residues are evolutionarily conserved from yeast to humans (Supplementary information, Figure S3 ), suggesting that all the Ash2L homologs share the similar SPRY fold as the human Ash2L SPRY . The deleted 44-residue loop F' between strands β11 and β12, is away from the structural core, and thus is dispensable for the stability of the Ash2L SPRY domain (Figures 1B). Of note, sequence alignment shows that the yeast Bre2 protein, a distant homolog of human Ash2L, contains two large loops, a 40-residue loop between strands β6 and β7 and another 112-residue loop connecting β11 and β12 (Supplementary information, Figure S3 ). Figure S5A and S5B). However, the affinity of the observed dimeric interface is too weak to stably hold two Ash2L SPRY molecules together in vitro (Supplementary information, Figure S5C and S5D). In addition, Ash2L dimerization appears to have no effect on the HMT activity of the MLL1 complex (Supplementary information, Figure S5E ). Further investigation is needed to clarify the in vivo function of Ash2L SPRY dimerization. Recent studies revealed that the SPRY domain of Ash2L recognizes a stretch of acidic residues of RbBP5 [5, 7] . We presumed that the interaction between Ash2L and RbBP5 is very likely mediated by electrostatic contacts. Consistent with this notion, our previous data showed that Arg343 of Ash2L is important for RbBP5 binding [5] . Arg343 is localized at a highly positively charged surface formed by strands β7, β8 and loop E of Ash2L SPRY ( Figure 1C ). This observation led us to hypothesize that this basic concaved surface on Ash2L SPRY might be the binding site for RbBP5. To test this idea, we examined whether mutations of residues on the predicted Ash2L-RbBP5 interface could weaken or disrupt the Ash2L-RbBP5 interaction. In support of our model and consistent with our previous results, alanine substitution of the conserved Arg343 of Ash2L SPRY was sufficient to completely abolish the interaction with RbBP5 in the ITC assay ( Figure 1D) . Similarly, alanine mutation of another arginine residue Arg367 also impaired the interaction ( Figure 1D ). In addition, several other positively charged residues of Ash2L SPRY (Lys369, Lys370, and Lys476) also play roles in RbBP5 interaction, as mutations of all these residues weaken the interaction to varying degrees ( Figure  1D ). Moreover, these RbBP5 binding-deficient mutants showed partial or complete loss of ability to stimulate the HMT activity of MLL1, in a manner consistent with the severity of the Ash2L-RbBP5 interaction defect (Figure 1E) . Taken together, we conclude that the identified basic surface on Ash2L SPRY is necessary for the binding to RbBP5. All the mutant proteins described above displayed unaltered biophysical properties, as analyzed by gel-filtration chromatography (data not shown), assuring that the altered affinity of the mutants for RbBP5 is not attributable to a change in the structural integrity of the resulting proteins. Ash2L SPRY employs a novel molecular surface to interact with RbBP5, as shown by the comparison with structures of other SPRY domain-containing complexes (Supplementary information, Figure S6 ), reinforcing the notion that SPRY domain is a diversified protein-protein interaction module.
Beside RbBP5, another important Ash2L-binding partner is DPY30 [4] . The C-terminus of Ash2L (residues 508-534) has been proposed to mediate the interaction with DPY30 [8] . We further characterized the Ash2L-DPY30 interaction by an in vitro GST-pull-down assay. Both the full-length DPY30 and its C-terminal dimerization domain (DPY30 DD ; residues 45-99) could efficiently pull-down Ash2L, suggesting that DPY30 DD is sufficient for the interaction with Ash2L (Supplementary information, Figure S7A ). Next, various constructs of Ash2L that contain the SPRY domain and end at different positions at the C-terminus of Ash2L were evaluated for their ability to interact with DPY30 DD . The Ash2L SPRY construct used for the structural study (residues 276-523) retained the binding activity with DPY30, whereas the construct ending at residue 510 failed to bind to DPY30 ( Figure  1F ). This result suggested that a short 14-residue C-terminal fragment of Ash2L (residues 510-523) is required for the interaction with DPY30. Notably, this short frag- Yong Chen et al. 601
npg ment was also found to be sufficient for DPY30 binding ( Figure 1F ). Although Ash2L 510-523 was included in the crystallization construct of Ash2L SPRY , residues 510-523 are not visible in the electron-density map, indicating that the Ash-2L DBM peptide is not part of the compact SPRY domain. DPY30 DD adopts a canonical four-helix-bundle conformation with extensive hydrophobic surface [9] . The structure of DPY30 DD is similar to that of PKA RIIa, the RIIa isoform of a cAMP-dependent protein kinase [10] . The two structures can be superimposed with an r.m.s.d. value of 2.1 Å (Supplementary information, Figure S7B ). In the PKA-RIIa/D-AKAP2 complex, the D-AKAP2 peptide forms a helical structure and binds to the hydrophobic cleft on the dimeric interface of PKA RIIa [10] . Notably, secondary structure prediction analysis suggested that, similar to the D-AKAP2 helix, residues 510 to 523 of Ash2L also likely adopt an α-helical structure (data not shown). Therefore, we hypothesized that Ash-2L DBM might bind to DPY30 in a similar manner to the D-AKAP2 helix in the PKA-RIIa/D-AKAP2 complex. Sequence alignment of Ash2L DBM with the D-AKAP2 peptide revealed that the hydrophobic residues that are involved in the complex formation in the PKA-RIIa/ D-AKAP2 complex are well-conserved in Ash2L (Supplementary information, Figure S7C ). Based on these analyses, we generated a model structure of Ash2L SPRY complexed with DPY30 DD ( Figure 1G ). In this model, the Ash2L-DPY30 interaction is mainly mediated by hydrophobic contacts; Ash2L residues Val509, Leu513, Val516, Leu517, and Val520 from one side of the Ash-2L DBM helix fit into the hydrophobic groove formed by a group of hydrophobic residues from the α1 helix of both DPY30 DD protomers (Leu57, Val61, Leu65, Leu66, and Met69) ( Figure 1G ). This is consistent with previous results that substitution of DPY30 Leu65 and Leu66 with glutamates completely abolished the interaction with Ash2L [8] . To further corroborate our structural model, we generated a series of Ash2L mutants and examined the effects of these mutations on the Ash2L-DPY30 interaction. Despite mutations of individual Ash2L residues on the Ash2L-DPY30 interface only slightly weakened the interaction, a triple Ash2L mutation L513E/L517E/ V520E completely disrupted the interface ( Figure 1H) . A definitive confirmation of this interaction model between Ash2L DBM and DPY30 DD has to wait until the atomic structure of the Ash2L DBM -DPY30 DD complex becomes available. Nonetheless, our structural and biochemical data showed that DPY30 and RbBP5 bind to different sites on Ash2L SPRY , suggesting that they mediate independent interactions with Ash2L. Consistent with this idea, addition of DPY30 had no effect on the interaction between Ash2L SPRY and RbBP5 (Supplementary information, Figure S7D ).
In the present work, we report the crystal structure of the C-terminal SPRY domain of human Ash2L. Our structural and biochemical analyses reveal a basic surface on Ash2L as the RbBP5-binding interface, and demonstrate that this interface is crucial for both RbBP5 binding and MLL1 methyltransferase activity regulation. We also determine the minimum motif of Ash2L that is required for DPY30 interaction, and propose a structural model for the Ash2L-DPY30 interaction. Together, these results provide a framework for the further investigation of the structure of the MLL complexes.
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